1089.7000 -13.60 (-1.23%)
NSE Sep 23, 2025 12:28 PM
Volume: 15,656
 

1089.70
-1.23%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs
More from Tatva Chintan Pharma Chem Ltd.
Recommended